Open AccessThe future of schizophrenia pharmacotherapeutics: Not so bleak
Author(s) -
William T. Carpenter
Publication year - 2012
Publication title -
mens sana monographs
Language(s) - English
Resource type - Journals
eISSN - 0973-1229
pISSN - 1998-4014
DOI - 10.4103/0973-1229.91298
Subject(s) - schizophrenia (object oriented programming) , psychopathology , psychology , neuroscience , pessimism , mechanism (biology) , psychosis , construct (python library) , chlorpromazine , disease , drug discovery , endophenotype , cognitive psychology , psychotherapist , psychiatry , medicine , bioinformatics , computer science , cognition , pharmacology , biology , philosophy , epistemology , pathology , programming language
Chlorpromazine efficacy in schizophrenia was observed 60 years ago. Advances in pharmacotherapy of this disorder have been modest with effectiveness still limited to the psychosis psychopathology and mechanism still dependent on dopamine antagonism. While a look backward may generate pessimism, future discovery may be far more robust. The near future will see significant changes in paradigms applied in discovery. Rather than viewing schizophrenia as a disease entity represented by psychosis, the construct will be deconstructed into component psychopathology domains. Each domain will represent a clinical target for aetiologic and therapeutic discovery. Research on pathophysiology will shift to the neural circuit level in relation to specific behavioural constructs. Progress at the molecular, genetic, cellular and network levels will be more robust. The behavioural paradigm will map on to the deconstructed clinical paradigm and in the process discovery will cut across current classification boundaries.